Antisoma: Eine brandheiße Story

Nachfolgend der Org.-Bericht auf dem sich die Empfehlung bezieht.
Endgültigen Bericht gibt es auf der Antisoma Webpage ab dem 30.09.03, dann auch hoffentlich in Deutsch. 

Interessant die Meldung zu R1549 (Smiley)


         Antisoma's preliminary results for the year ended 30 June 2003


18 September 2003, London, UK: Antisoma plc (LSE: ASM), the biopharmaceutical
company specialising in novel anti-cancer drugs, today announces its preliminary
results for the year ended 30 June 2003.

Highlights - a year of transformation

Ground-breaking alliance formed with Roche

     • Injection of £27.3 million cash and reduced cash burn
     • Potential for future milestone and royalty payments
     • Clear route to market established for products

Existing pipeline advanced

     • Lead product R1549 close to completing pivotal efficacy study
     • Broad development of R1550 begun with breast cancer study

Pipeline strengthened bynew addition

     • Licensing of telomerase inhibitor programme from Cancer Research
       Technology Ltd (in September 2003)

Financial highlights

     • Full-year net loss reduced significantly to £3.3 million (2002:
       £13.2 million)
• Revenues increased substantially to £11.8 million (2002: £2.2
       million)
     • Cash and cash equivalents at 30 June 2003 of £34.0 million (2002:

       £18.9 million)


Commenting on the results, Glyn Edwards, Chief Executive Officer of Antisoma,
said: 'Antisoma has achieved a step change in its position over the past 12
months. Formation of a broad strategic alliance with Roche has opened up a clear
route to market for our products and greatly improved our financial position,
leaving us well placed to exploit our maturing pipeline and to build on our
proven track record as a seeker and developer of innovative approaches to the
treatment of cancer. We are now only months away from knowing the result of our
pivotal study of R1549 in ovarian cancer.'

zu den Ergebnissen vom 18.09.03 gabs auch noch ein Interview vom CEO


INTERVIEW Antisoma CEO Looking For Fast-track FDA Approval For Cancer Drug
Thursday, September 18, 2003


LONDON (AFX) - Antisoma PLC chief executive Glyn Edwards reckons the company's lead drug used to treat ovarian cancer will probably be fast-tracked by the US Food & Drug Administration.

And he admitted that if everything went to plan, the drug could be approved and ready for launch by the first half of 2005.

"That is possible," he said in an interview with AFX News.

"But in my experience nothing goes totally to the shortest possible time line," he also cautioned.

"It is possible and I dream of things like that."

Antisoma has partnered with Roche to develop R1549, originally known to UK investors as Pemtumomab, though the co-operation and 27.3 mln stg the Swiss drugs giant paid over to seal the alliance also covers other potential cancer products.

Currently the pair are putting R1549 through its most crucial trial -- the survival study of monoclonal antibody radio therapy, or SMART study.

This will be the final assessment of the drug's efficacy before it is submitted to the US and EU authorities for approval and 400 ovarian cancer patients in the US, Europe and Australia are receiving the treatment.

If it goes into commercial production it will trigger a hefty, but as yet undisclosed, milestone payment as well as royalties. "It would obviously completely transform the company," Edwards said.

Analysts currently reckon R1549 could be worth 200-400 mln stg a year in peak sales.

Edwards was speaking after the company unveiled full-year results which have been completely transformed by the Roche tie-up.

Shared research and development means it is now forecast to burn 10 mln stg a year compared with 16 mln before the deal and probably has funds to last until the end of 2006.

And the Antisoma CEO said there it may never be a need to come back to the market for fresh cash if the SMART trial goes to plan.

"We don't need to do a fundraising for the foreseeable future and it is conceivable that if our lead product is successful that cash coming in from that will come in before the cash runs out from normal operations," Edwards said.



Author: IAN LYALL
Provided by: AFX News Limited
Copyright 2003 AFX News Limited. All Rights Reserved.  


das wars für heut
viel spassss beim lesen

und wer zu faul zum lesen ist,
unter 0,60 € sind kaufkurse  !!!